Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Solid Tumor × tilsotolimod × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Interventions

pembrolizumab 2 zimberelimab 1 tislelizumab 1 tilsotolimod 1 sintilimab 1 sacituzumab govitecan 1 niraparib 1 cobimetinib 1 cedazuridine 1 atezolizumab 1 Radiosurgery 1 Proton Therapy 1 Nivolumab 1 Ipilimumab 1 Injections 1 Everolimus 1 Decitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03865082 2022-02-17

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Idera Pharmaceuticals, Inc.

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡